Please ensure Javascript is enabled for purposes of website accessibility

Charlotte's Web Sponsoring New CBD Study

By Eric Volkman - Jun 9, 2020 at 9:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The research is aimed at providing the Food and Drug Administration with scientific data on the substance.

Charlotte's Web (CWBHF 6.64%) is putting its money where its mouth is with cannabidiol (CBD). The company, which specializes in "wellness" products made from the substance, announced Tuesday it is sponsoring a research study on the effects of CBD. It did not specify how much it is contributing with this sponsorship.

The study, being conducted by privately held clinical research company ValidCare, is aimed at determining whether and how daily CBD use affects the human body. Further details of the planned study, including its timing, were not provided.

A field of hemp plants.

Image source: Getty Images.

Seven marijuana companies active in the CBD segment, including Charlotte's Web, are involved in the study. Of the seven, Charlotte's Web is the only one that is publicly traded.

The research push comes from a request from the Food and Drug Administration seeking science-based data on CBD to help guide its regulatory approach to the substance. Last November, the FDA published a consumer update on CBD products, warning that their use could result in health problems such as liver injury, among other difficulties.

"As the market share leader, anchored in science, sponsoring ValidCare's study made strategic sense for us," Charlotte's Web wrote in its press release heralding its involvement. "This research will provide important clinical data to guide our entire industry while also showing the FDA we've heard their requests and are answering their questions with precise data."

CBD derived from hemp is fully legal in the U.S., having been sanctioned by the wide-ranging Farm Bill passed into law in late 2018.

Investors might not be happy about Charlotte's Web spending its time and capital on sponsoring the study. On Tuesday, the company's shares slumped by almost 6%, exceeding the decline of the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Charlotte's Web. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Charlotte's Web Holdings, Inc. Stock Quote
Charlotte's Web Holdings, Inc.
$0.69 (6.64%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.